Three things happened in protein degradation over the past five days. Each one would be a headline on its own. Together, they tell you where this field is headed.
First: the FDA granted Kymera Therapeutics a second Fast Track designation for KT-621, their oral STAT6 degrader. The first was for atopic dermatitis. This one is for moderate to severe eosinophilic asthma. Phase 2b trials are running in both indications with data expected in 2027. Preclinical studies showed picomolar potency and complete STAT6 degradation in blood and skin.
Second: Gilead exercised its option to exclusively license KT-200, Kymera’s oral CDK2 molecular glue degrader, triggering a $45 million milestone payment with up to $750 million more on the table. Gilead takes over IND-enabling studies and plans to file by 2027.
Third: Neomorph closed a $100 million Series B for its molecular glue degrader platform. Deerfield led, with Regeneron Ventures, Longwood Fund, and Alexandria Venture Investments participating. Their lead asset, NEO-811, is already in Phase 1/2 for clear cell renal cell carcinoma.
Two therapeutic areas. Three pharma touchpoints. Over $145 million moving in five days.
Kymera Therapeutics pipeline
KT-621 (STAT6 degrader)
Oral · Atopic derm + asthma · 2x Fast Track · Wholly owned
KT-579 (IRF5 degrader)
Oral · Lupus, RA, autoimmune · Wholly owned
KT-485 / SAR447971 (IRAK4 degrader)
Oral · 2nd gen · Immuno-inflammatory · Sanofi partnership ($150M upfront, $2B+)
KT-200 (CDK2 molecular glue)
Oral · Oncology · Gilead licensed ($45M milestone, $750M+ potential)
Four degrader programs spanning immunology and oncology from a single E3 ligase mapping engine
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you, contextualized and written directly to you, so you cut through the noise and immediately understand why it matters.
Kymera has quietly become one of the most impressive platform stories in biotech.
Sanofi is paying for the IRAK4 degrader program ($150 million upfront, $2 billion+ in milestones).
Gilead is paying for CDK2. The FDA gave them two Fast Tracks. They’re sitting on roughly $1.6 billion in cash after a $602 million raise in December. Four degrader programs spanning immunology and oncology, all from a single E3 ligase mapping engine.
Neomorph represents a different flavor of the same thesis.
Molecular glue degraders work differently from Kymera’s heterobifunctional approach. They stabilize interactions between a target protein and an E3 ligase directly, without the two-armed linker design. The mechanism was discovered by accident (thalidomide turned out to be a molecular glue).
Companies like Neomorph and Ternary Therapeutics are engineering it on purpose. =
When Regeneron’s venture arm writes a check for a molecular glue degrader company, you know the field has moved past “interesting science.”
The broader ecosystem we’re tracking across the FLYTE Intelligence database now includes 145 targeted protein degradation companies.
Some notable examples?
Arvinas and C4 Therapeutics are running Phase 2 programs. Biotheryx and Frontier Medicines are in Phase 1. Preclinical companies like Ambagon (molecular glue stabilizers via 14-3-3 biology), Degron Therapeutics (AI-enabled molecular glues), and 76Bio (mRNA-based degraders delivered by lipid nanoparticles – not really “protein degraders” but we’ll put them here for now) are building entirely new approaches.
A year ago, raising money for a degrader startup meant explaining why the chemistry would work. In April 2026, it means explaining why yours is different from the other 144. That’s the shift.
